Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1

References

• D’Amours D, Desnoyers S, D’Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999, 342 (Pt 2), 249–268.
   PubMedGoogle Scholar
• Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem 2000, 275, 40974–40980.
   PubMed Web of Science ®Google Scholar
• Althaus FR, Kleczkowska HE, Malanga M, Müntener CR, Pleschke JM, Ebner M, Auer B. Poly ADP-ribosylation: a DNA break signal mechanism. Mol Cell Biochem 1999, 193, 5–11.
   PubMedGoogle Scholar
• de Murcia G, Ménissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994, 19, 172–176.
   PubMed Web of Science ®Google Scholar
• Simonin F, Höfferer L, Panzeter PL, Muller S, de Murcia G, Althaus FR. The carboxyl-terminal domain of human poly(ADP-ribose) polymerase. Overproduction in Escherichia coli, large scale purification, and characterization. J Biol Chem 1993, 268, 13454–13461.
   PubMedGoogle Scholar
• Mendoza-Alvarez H, Alvarez-Gonzalez R. Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J Biol Chem 1993, 268, 22575–22580.
   PubMed Web of Science ®Google Scholar
• Panzeter PL, Althaus FR. DNA strand break-mediated partitioning of poly(ADP-ribose) polymerase function. Biochemistry 1994, 33, 9600–9605.
   PubMedGoogle Scholar
• Desmarais Y, Ménard L, Lagueux J, Poirier GG. Enzymological properties of poly(ADP-ribose)polymerase: characterization of automodification sites and NADase activity. Biochim Biophys Acta 1991, 1078, 179–186.
   PubMedGoogle Scholar
• Southan GJ, Szabó C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 2003, 10, 321–340.
   PubMed Web of Science ®Google Scholar
• Beneke S, Diefenbach J, Bürkle A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 2004, 111, 813–818.
   PubMed Web of Science ®Google Scholar
• Ferraris D, Ficco RP, Dain D, Ginski M, Lautar S, Lee-Wisdom K, Liang S, Lin Q, Lu MX, Morgan L, Thomas B, Williams LR, Zhang J, Zhou Y, Kalish VJ. Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries. Bioorg Med Chem 2003, 11, 3695–3707.
   PubMed Web of Science ®Google Scholar
• Iwashita A, Hattori K, Yamamoto H, Ishida J, Kido Y, Kamijo K, Murano K, Miyake H, Kinoshita T, Warizaya M, Ohkubo M, Matsuoka N, Mutoh S. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett 2005, 579, 1389–1393.
   PubMed Web of Science ®Google Scholar
• Steinhagen H, Gerisch M, Mittendorf J, Schlemmer KH, Albrecht B. Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett 2002, 12, 3187–3190.
   PubMed Web of Science ®Google Scholar
• Jagtap PG, Southan GJ, Baloglu E, Ram S, Mabley JG, Marton A, Salzman A, Szabó C. The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg Med Chem Lett 2004, 14, 81–85.
   PubMed Web of Science ®Google Scholar
• Loh VM Jr, Cockcroft XL, Dillon KJ, Dixon L, Drzewiecki J, Eversley PJ, Gomez S, Hoare J, Kerrigan F, Matthews IT, Menear KA, Martin NM, Newton RF, Paul J, Smith GC, Vile J, Whittle AJ. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 2005, 15, 2235–2238.
   PubMed Web of Science ®Google Scholar
• Ferraris D, Ko YS, Pahutski T, Ficco RP, Serdyuk L, Alemu C, Bradford C, Chiou T, Hoover R, Huang S, Lautar S, Liang S, Lin Q, Lu MX, Mooney M, Morgan L, Qian Y, Tran S, Williams LR, Wu QY, Zhang J, Zou Y, Kalish V. Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J Med Chem 2003, 46, 3138–3151.
   PubMed Web of Science ®Google Scholar
• Ferraris D, Ficco RP, Pahutski T, Lautar S, Huang S, Zhang J, Kalish V. Design and Synthesis of Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors. Part 3. In vitro Evaluation of 1,3,4,5-Tetrahydro-benzo[c][1,6]- and [c][1,7]- naphthyridin-6-ones Bioorg Med Chem Lett 2003, 13, 2513–2518.
   Google Scholar
• Zeng H, Zhang H, Jang F, Zhao L, Zhang J. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking. Chem Biol Drug Des 2011, 78, 333–352.
   PubMed Web of Science ®Google Scholar
• Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988, 110, 5959–5967.
   PubMed Web of Science ®Google Scholar
• Cramer RD 3rd, Patterson DE, Bunce JD. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 1998, 7, 18–25.
   Google Scholar
• Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994, 37, 4130–4146.
   PubMed Web of Science ®Google Scholar
• Lord AM, Mahon MF, Lloyd MD, Threadgill MD. Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor. J Med Chem 2009, 52, 868–877.
   PubMedGoogle Scholar
• Kouji H, Yoshiyuki K, Hirofumi Y, Junya I, Kazunori K, Kenji M, Mitsuru O, Takayoshi K, Akinori I, Kayoko M, Syunji Y, Nobuya M, Yoshinori T, Hiroshi M. Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem 2004 47, 4151–4154.
   PubMedGoogle Scholar
• Jagtap PG, Baloglu E, Southan GJ, Mabley JG, Li H, Zhou J, van Duzer J, Salzman AL, Szabó C. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem 2005, 48, 5100–5103.
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O’Connor MJ, Smith GC, Martin NM. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008, 51, 6581–6591.
   PubMed Web of Science ®Google Scholar
• Wold S, Johansson A, Cochi M. (1993). 3D-QSAR in drug design: theory, methods and application. In: Kubinyi H, (ed.). PLS-Partial least squares projection tolatent structures. Lieden: ESCOM, 523–550.
   Google Scholar
• Park CH. DOI: 10.2210/pdb2rd6/pdb (Article to be published). (cited in HYPERLINK “http://www.rcsb.org” www.rcsb.org, pdb id: 2rd6)
   Google Scholar
• Schrödinger, LLC. (2010). New York: Glide Version 5.6.
   Google Scholar
• Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004, 47, 1739–1749.
   PubMed Web of Science ®Google Scholar
• Taverna DM, Goldstein RA. Why are proteins marginally stable? Proteins 2002, 46, 105–109.
   PubMed Web of Science ®Google Scholar
• Sybyl-X1.2. (2010). Tripos Associates. St. Louis (MO).
   Google Scholar
• Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity – a rapid access to atomic charges. Tetrahedron 1980 36, 3219–3228.
   Web of Science ®Google Scholar